Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma

Sorafenib has been demonstrated to improve survival rate in patients with advanced hepatocellular carcinoma (HCC); however, the survival benefit remains modest and the response rates remain poor. Transarterial chemoembolization (TACE) may be used for the treatment of advanced HCC with well-preserved...

Descripción completa

Detalles Bibliográficos
Autores principales: SHAO, WENBO, ZHANG, FENGJUAN, CONG, NING, LI, JINPENG, SONG, JINLONG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186530/
https://www.ncbi.nlm.nih.gov/pubmed/25289106
http://dx.doi.org/10.3892/ol.2014.2512
_version_ 1782338076843966464
author SHAO, WENBO
ZHANG, FENGJUAN
CONG, NING
LI, JINPENG
SONG, JINLONG
author_facet SHAO, WENBO
ZHANG, FENGJUAN
CONG, NING
LI, JINPENG
SONG, JINLONG
author_sort SHAO, WENBO
collection PubMed
description Sorafenib has been demonstrated to improve survival rate in patients with advanced hepatocellular carcinoma (HCC); however, the survival benefit remains modest and the response rates remain poor. Transarterial chemoembolization (TACE) may be used for the treatment of advanced HCC with well-preserved liver function and has a high local tumor control rate. We hypothesized that patients with advanced HCC may benefit from the combination of sorafenib with TACE. A retrospective study was conducted involving patients with advanced HCC, who had received at least one TACE session. Patients subsequently received 400 mg sorafenib twice per day and were monitored monthly. A dose reduction from 400 to 200 mg of sorafenib twice per day was permitted. The overall survival and side effects were subsequently followed up. In total, 38 patients were included from April 1st, 2009 to March 31st, 2012. All patients were treated with sorafenib after TACE was performed. As of March 31st, 2013, seven patients remained on sorafenib, and were censored at that time point. The median overall survival time was 12 months (95% confidence interval, 6.3–17.7 months). The sorafenib dose was reduced temporarily in 32 patients (84.2%). The most common toxicities were dermatological adverse effects (94.7%), diarrhea (63.2%) and alopecia (26.3%). The survival benefit of sorafenib combined with TACE for advanced HCC is promising, with no intolerable adverse events, provided that dose adjustment is permitted.
format Online
Article
Text
id pubmed-4186530
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-41865302014-10-06 Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma SHAO, WENBO ZHANG, FENGJUAN CONG, NING LI, JINPENG SONG, JINLONG Oncol Lett Articles Sorafenib has been demonstrated to improve survival rate in patients with advanced hepatocellular carcinoma (HCC); however, the survival benefit remains modest and the response rates remain poor. Transarterial chemoembolization (TACE) may be used for the treatment of advanced HCC with well-preserved liver function and has a high local tumor control rate. We hypothesized that patients with advanced HCC may benefit from the combination of sorafenib with TACE. A retrospective study was conducted involving patients with advanced HCC, who had received at least one TACE session. Patients subsequently received 400 mg sorafenib twice per day and were monitored monthly. A dose reduction from 400 to 200 mg of sorafenib twice per day was permitted. The overall survival and side effects were subsequently followed up. In total, 38 patients were included from April 1st, 2009 to March 31st, 2012. All patients were treated with sorafenib after TACE was performed. As of March 31st, 2013, seven patients remained on sorafenib, and were censored at that time point. The median overall survival time was 12 months (95% confidence interval, 6.3–17.7 months). The sorafenib dose was reduced temporarily in 32 patients (84.2%). The most common toxicities were dermatological adverse effects (94.7%), diarrhea (63.2%) and alopecia (26.3%). The survival benefit of sorafenib combined with TACE for advanced HCC is promising, with no intolerable adverse events, provided that dose adjustment is permitted. D.A. Spandidos 2014-11 2014-09-09 /pmc/articles/PMC4186530/ /pubmed/25289106 http://dx.doi.org/10.3892/ol.2014.2512 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
SHAO, WENBO
ZHANG, FENGJUAN
CONG, NING
LI, JINPENG
SONG, JINLONG
Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
title Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
title_full Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
title_fullStr Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
title_full_unstemmed Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
title_short Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
title_sort transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186530/
https://www.ncbi.nlm.nih.gov/pubmed/25289106
http://dx.doi.org/10.3892/ol.2014.2512
work_keys_str_mv AT shaowenbo transarterialchemoembolizationcombinedwithsorafenibforadvancedhepatocellularcarcinoma
AT zhangfengjuan transarterialchemoembolizationcombinedwithsorafenibforadvancedhepatocellularcarcinoma
AT congning transarterialchemoembolizationcombinedwithsorafenibforadvancedhepatocellularcarcinoma
AT lijinpeng transarterialchemoembolizationcombinedwithsorafenibforadvancedhepatocellularcarcinoma
AT songjinlong transarterialchemoembolizationcombinedwithsorafenibforadvancedhepatocellularcarcinoma